ClinConnect ClinConnect Logo
Search / Trial NCT07028112

Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.

Launched by ASSISTANCE PUBLIQUE - HÔPITAUX DE PARIS · Jun 11, 2025

Trial Information

Current as of June 26, 2025

Not yet recruiting

Keywords

Iron Overload Liver Fibrosis Elastography Long Term Complications Allogeneic Hematopoietic Stem Cell Transplantation Graft Versus Host Disease

ClinConnect Summary

This study is looking at whether having too much iron in the body—a condition called iron overload—affects the chances of developing liver problems in people who had a special type of stem cell transplant called an allogeneic hematopoietic stem cell transplant (HSCT) at least 10 years ago. The researchers will review the health records of about 400 to 500 adults who had their transplant at Hôpital Saint Louis between 2004 and 2014. They will also do some simple tests during a scheduled visit, like blood tests and a painless scan to check how stiff the liver is, which helps show liver health. The main goal is to find out if iron overload leads to more liver issues over the long term, and the study will also look at other factors that might increase risk and how well treatments to reduce iron have worked in the past.

People who might join the study are adults (18 years or older) who had their transplant at Hôpital Saint Louis during the specified years, are still alive and regularly attending follow-up visits, and have health insurance. Participants will be asked to share their medical history and undergo some routine lab tests and liver scans during one visit. This research could help doctors understand if monitoring and treating iron overload early might prevent liver problems many years after transplant, potentially improving long-term health for survivors.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Age ≥ 18 years at enrollment
  • Allogeneic HSCT performed at Hôpital Saint Louis between 2004/01/01 and 2014/12/31
  • Alive and attending routine annual follow up within the two years of the study
  • Having given his non-opposition to study after understand overall aims
  • With health insurance coverage
  • Follow up consultation at Saint-Louis Hospital
  • Exclusion Criteria:
  • Patient under legal protection (protection of the court, or in curatorship or guardianship).
  • not in relapse of the hematological disease at the time of inclusion.
  • • Patients under 45 Kg

About Assistance Publique Hôpitaux De Paris

Assistance Publique - Hôpitaux de Paris (AP-HP) is a leading public hospital system in France, renowned for its commitment to healthcare excellence and innovative medical research. As a prominent clinical trial sponsor, AP-HP plays a pivotal role in advancing medical knowledge and improving patient care through rigorous scientific investigations across a wide range of therapeutic areas. With a focus on collaboration and interdisciplinary approaches, AP-HP leverages its extensive network of hospitals and expert clinicians to facilitate high-quality clinical trials that adhere to the highest ethical and regulatory standards, ultimately aiming to translate research findings into tangible health benefits for diverse patient populations.

Locations

Patients applied

0 patients applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported